Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 200815-49-2
2. Brovana
3. (r,r)-arformoterol Tartrate
4. Arformoterol Tartrate [usan]
5. 5p8vj2i235
6. Arformoterol Tartrate (usan)
7. Formamide, N-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2r,3r)-2,3-dihydroxybutanedioate (1:1)
8. (r,r)-formoterol Tartrate
9. (-)-n-(2-hydroxy-5-((1r)-1-hydroxy-2-(((1r)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide Hydrogen (2r,3r)-2,3-dihydroxybutanedioate (salt)
10. Formamide, N-(2-hydroxy-5-((1r)-1-hydroxy-2-(((1r)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1) (salt)
11. N-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide (2r,3r)-2,3-dihydroxybutanedioate (1:1) (salt)
12. Brovana Inhalation Solution
13. Unii-5p8vj2i235
14. Brovana (tn)
15. Arformotero Ltartrate
16. Dtxsid80173903
17. Arformoterol Tartrate [vandf]
18. S5217
19. Arformoterol Tartrate [mart.]
20. Akos005145740
21. Arformoterol Tartrate [who-dd]
22. Ccg-269651
23. Arformoterol Tartrate, >=98% (hplc)
24. Ba171831
25. Bs-42158
26. Arformoterol Tartrate [orange Book]
27. Formoterol R,r-form L-tartrate [mi]
28. D02981
29. 815f492
30. Q-101035
31. Q27262686
32. (2r,3r)-2,3-dihydroxybutanedioic Acid;n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
33. (r,r)-formoterol Tartrate; N-(2-hydroxy-5-((1r)-1-hydroxy-2-(((1r)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide (2r,3r)-2,3-dihydroxybutanedioate (1:1)
34. [(2r)-2-(3-formamido-4-hydroxyphenyl)-2-hydroxyethyl]-[(2r)-1-(4-methoxyphenyl)propan-2-yl]azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate
35. N-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (2r,3r)-2,3-dihydroxybutane Dioate
36. N-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (2r,3r)-2,3-dihydroxybutanedioate
37. N-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide L-tartrate
Molecular Weight | 494.5 g/mol |
---|---|
Molecular Formula | C23H30N2O10 |
Hydrogen Bond Donor Count | 8 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 11 |
Exact Mass | 494.19004516 g/mol |
Monoisotopic Mass | 494.19004516 g/mol |
Topological Polar Surface Area | 206 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 521 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Brovana |
PubMed Health | Arformoterol (By breathing) |
Drug Classes | Bronchodilator |
Active Ingredient | Arformoterol tartrate |
Dosage Form | Solution |
Route | Inhalation |
Strength | eq 0.015mg base/2ml |
Market Status | Prescription |
Company | Sunovion |
2 of 2 | |
---|---|
Drug Name | Brovana |
PubMed Health | Arformoterol (By breathing) |
Drug Classes | Bronchodilator |
Active Ingredient | Arformoterol tartrate |
Dosage Form | Solution |
Route | Inhalation |
Strength | eq 0.015mg base/2ml |
Market Status | Prescription |
Company | Sunovion |
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-04-12
Pay. Date : 2018-07-17
DMF Number : 32990
Submission : 2018-07-25
Status : Active
Type : II
NDC Package Code : 64567-0020
Start Marketing Date : 2018-07-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2022-03-24
Registration Number : 20220324-211-J-1236
Manufacturer Name : INKE, SA
Manufacturer Address : C/ Argent 1, Area industrial del Llobregat 08755, Castellbisbal (Barcelona) Spain
Available Reg Filing : CN |
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-07-14
Pay. Date : 2022-03-17
DMF Number : 36435
Submission : 2022-05-16
Status : Active
Type : II
NDC Package Code : 64567-0020
Start Marketing Date : 2018-07-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2022-03-24
Registration Number : 20220324-211-J-1236
Manufacturer Name : INKE, SA
Manufacturer Address : C/ Argent 1, Area industrial del Llobregat 08755, Castellbisbal (Barcelona) Spain
Available Reg Filing : CN |
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-10-24
Pay. Date : 2018-07-26
DMF Number : 28013
Submission : 2014-03-15
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm :
NDC Package Code : 14501-0077
Start Marketing Date : 2012-07-02
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-06-09
Pay. Date : 2015-03-27
DMF Number : 28868
Submission : 2015-03-27
Status : Active
Type : II
NDC Package Code : 66039-909
Start Marketing Date : 2015-03-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-05-15
Pay. Date : 2014-05-02
DMF Number : 22968
Submission : 2009-08-19
Status : Active
Type : II
Date of Issue : 2022-06-08
Valid Till : 2025-09-08
Written Confirmation Number : WC-0144
Address of the Firm :
NDC Package Code : 53104-7731
Start Marketing Date : 2017-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2022-07-28
Valid Till : 2025-07-02
Written Confirmation Number : WC-0227
Address of the Firm :
Date of Issue : 2020-01-28
Valid Till : 2022-09-08
Written Confirmation Number : WC-0144A5
Address of the Firm :
NDC Package Code : 53104-7731
Start Marketing Date : 2017-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Complete
Rev. Date : 2022-07-14
Pay. Date : 2022-03-17
DMF Number : 36435
Submission : 2022-05-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-04-12
Pay. Date : 2018-07-17
DMF Number : 32990
Submission : 2018-07-25
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-15
Pay. Date : 2014-05-02
DMF Number : 22968
Submission : 2009-08-19
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-06-09
Pay. Date : 2015-03-27
DMF Number : 28868
Submission : 2015-03-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-10-24
Pay. Date : 2018-07-26
DMF Number : 28013
Submission : 2014-03-15
Status : Active
Type : II
Date of Issue : 2022-06-08
Valid Till : 2025-09-08
Written Confirmation Number : WC-0144
Address of the Firm : Plot. D-7 MIDC, Kurkumbh, Dist. Pune-413802
Date of Issue : 2020-01-28
Valid Till : 2022-09-08
Written Confirmation Number : WC-0144A5
Address of the Firm : Plot. D-7 MIDC, Kurkumbh, Dist. Pune-413802
Date of Issue : 2022-07-28
Valid Till : 2025-07-02
Written Confirmation Number : WC-0227
Address of the Firm : Plot No. J-73, MIDC, Tarapur, Boisar, Dist- Palghar 401506, Maharashtra, India
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm : Sy. Nos: 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Man...
Date of Issue : 2019-07-15
Valid Till : 2022-07-14
Written Confirmation Number : WC-0021
Address of the Firm : Sy. No.317&323, Rudraram Village, Patancheru Mandal, Sangaredy District-502329 T...
Details:
The acquisition of Brovana® (arformoterol tartrate) Inhalation Solution and Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol brands expands Lupin’s portfolio of inhalation products in the U.S. and strengthens the company’s presence in the respiratory therapy area.
Lead Product(s): Arformoterol Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Brovana
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Lupin Ltd
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 20, 2022
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : $75.0 million
Deal Type : Acquisition
Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion
Details : The acquisition of Brovana® (arformoterol tartrate) Inhalation Solution and Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol brands expands Lupin’s portfolio of inhalation products in the U.S. and strengthens the company’s presence in the re...
Brand Name : Brovana
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 20, 2022
Details:
Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 ml is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema.
Lead Product(s): Arformoterol Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Arformoterol Tartrate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 ml is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema.
Brand Name : Arformoterol Tartrate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2022
Details:
Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana®.
Lead Product(s): Arformoterol Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cipla Receives Final Approval for Generic Version Of Sunovion Pharmaceuticals, Inc.'s Brovana®
Details : Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana®.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2021
Details:
Arformoterol Tartrate Inhalation Solution 15mcg/2mL, is indicated for the long-term, twice daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It is for use by nebulization only.
Lead Product(s): Arformoterol Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Launches Authorized Generic Version of Brovana® in the United States
Details : Arformoterol Tartrate Inhalation Solution 15mcg/2mL, is indicated for the long-term, twice daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It is for us...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 03, 2021
(R)-N-(2-(Benzyloxy)-5-(2-bromo-1-hydroxyethyl)phe...
CAS Number : 201677-59-0
End Use API : Arformoterol Tartrate
About The Company : Hiray Pharma Solutions is an international end-to-end CDMO, facilitating the development and manufacturing of important drug products and key intermediates arou...
(R)-N-Benzyl-1-(4-methoxyphenyl)propan-2-amine (S)...
CAS Number : 188690-84-8
End Use API : Arformoterol Tartrate
About The Company : Hiray Pharma Solutions is an international end-to-end CDMO, facilitating the development and manufacturing of important drug products and key intermediates arou...
N-[5-bromo-2-(2-nitrophenyl)sulfanyl-phenyl]formam...
CAS Number : 201677-59-0
End Use API : Arformoterol Tartrate
About The Company : With nearly seven decades of manufacturing expertise, Speichim Processing actively formulates circular economy strategies by reclaiming waste and chemical produ...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2024-06-03
Application Number : 215032
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2024-04-02
Application Number : 214901
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2022-05-10
Application Number : 214779
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2021-06-22
Application Number : 213762
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2024-05-17
Application Number : 216303
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : BROVANA
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2006-10-06
Application Number : 21912
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2022-02-07
Application Number : 213068
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2022-11-15
Application Number : 216128
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2021-11-09
Application Number : 200293
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ARFORMOTEROL TARTRATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : EQ 0.015MG BASE/2ML
Packaging :
Approval Date : 2022-03-02
Application Number : 214736
Regulatory Info : RX
Registration Country : USA
Related Excipient Companies
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : NaCl Multi-compendial Low...
Application : Parenteral
Excipient Details : A & C's Sodium Chloride multi-compendial low endotoxin is an excipient meeting USP-NF, EP, BP and JP monographs.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Low Endotoxin
Ingredient(s) : Sodium Chloride Excipient
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Sodium Chloride USP
Application : Parenteral
Excipient Details : A & C's Sodium Chloride is an excipient meeting the USP monograph.
Dosage Form : Tablet
Grade : Oral
Brand Name : Sodium Citrate Dihydrate ...
Application : Controlled & Modified Release
Excipient Details : A & C's Sodium Citrate Dihydrate multi-compendial is a trisodium salt of citric acid.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Not Available
Ingredient(s) : Sodium Citrate Dihydrate Excipient
Dosage Form : Tablet
Grade : Oral
Brand Name : Sodium Citrate Dihydrate ...
Application : Controlled & Modified Release
Excipient Details : A & C's Sodium Citrate Dihydrate USP-NF is a trisodium salt of citric acid.
Pharmacopoeia Ref : USP/NF
Technical Specs : Not Available
Ingredient(s) : Sodium Citrate Dihydrate Excipient
Excipients by Applications
Brand Name : Sodium Chloride USP
Application : Parenteral
Excipient Details : A & C's Sodium Chloride is an excipient meeting the USP monograph.
Brand Name : NaCl Multi-compendial Low Endotoxin
Application : Parenteral
Excipient Details : A & C's Sodium Chloride multi-compendial low endotoxin is an excipient meeting USP-NF, EP, BP and JP monographs.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Low Endotoxin
Ingredient(s) : Sodium Chloride Excipient
Global Sales Information
Market Place
Reply
26 Jan 2022
Reply
15 Jun 2021
REF. STANDARDS & IMPURITIES
CAS Number : 1795135-61-3
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : A0131.01
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?